diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5633diaendo-5633Research ArticleСтатьиArticlesСахарный диабет и гормональная энтерология: путь в прекрасное далеко?Sakharnyy diabet i gormonal'naya enterologiya: put' v prekrasnoe daleko?АлександровАндрей АлексеевичAleksandrovAndrey Alexeevichndocar@mail.ruФГУ Эндокринологический научный центр, МоскваEndocrinological Research Centre, Moscow201115062011142№2 (2011)4148Copyright © Александров А.А., 20112011Александров А.А.Aleksandrov A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5633

Желудочно-кишечный тракт способен вырабатывать гормоны, определяющие секрецию инсулина из поджелудочной железы под воз-действием глюкозы. Одним из них является глюкагоноподобный пептид-1. Искусственный аналог этого гормона - лираглутид - об-ладает рядом свойств, помогающих контролировать углеводный обмен у больных сахарным диабетом 2 типа и имеет подтвержденныеположительные эффекты на факторы риска развития сердечно-сосудистых осложнений.

The gastrointestinal tract produces hormones that influence glucose-induced pancreatic insulin secretion. One of them is glucagon-like peptide 1.Its synthetic analog, liraglutide, has properties that promote metabolic control in patients with type 2 diabetes mellitus and have beneficial effecton the risk factors of cardiovascular complications.

сахарный диабетдиффузная пептидергическая нейроэндокринная системаинкретиныглюкогоноподобный пептид 1сердечно-сосудистые осложненияdiabetes mellitusdiffuse peptidergic neuroendocrine systemincretinsglucagon-like peptide 1cardiovascular complicationsReferencesBayliss W.M., Starling E.H. The mechanism of pancreatic secretion // J. Physiol. - 1902. - № 28. - Р. 325-353.Bayliss W.M., Starling E.H. The mechanism of pancreatic secretion // J. Physiol. - 1902. - № 28. - Р. 325-353.Solcia E., Capella C., Fiocca R., Sessa F., La Rosa S., Rindi G. Disorders of the endocrine system / In: Ming S.C., Goldman H. (eds). Pathology of the gastrointestinal tract. Saunders. Philadelphia. - 1980. - Р. 240-263.Solcia E., Capella C., Fiocca R., Sessa F., La Rosa S., Rindi G. Disorders of the endocrine system / In: Ming S.C., Goldman H. (eds). Pathology of the gastrointestinal tract. Saunders. Philadelphia. - 1980. - Р. 240-263.Solcia E., Polak J.M., Pearse A.G.E., Forssmann W.G. Larsson L.I., et al. Lausanne 1977 classification of gastroenteropancreatic endocrine cells / In: gut Hormones, edited by S.R. Bloom, Churchill Livingstone. Edinburgh. - 1978. - Р. 40-48.Solcia E., Polak J.M., Pearse A.G.E., Forssmann W.G. Larsson L.I., et al. Lausanne 1977 classification of gastroenteropancreatic endocrine cells / In: gut Hormones, edited by S.R. Bloom, Churchill Livingstone. Edinburgh. - 1978. - Р. 40-48.Rindi G., Capella C., Solcia E. Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors // J. Mol. Med. - 1998. - № 76. - Р. 413-420.Rindi G., Capella C., Solcia E. Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors // J. Mol. Med. - 1998. - № 76. - Р. 413-420.Feyrter F. Uber diffuse endocrine eitheliale organe / J.A. Barth. - Leipzig. - 1938. - Р. 6-17.Feyrter F. Uber diffuse endocrine eitheliale organe / J.A. Barth. - Leipzig. - 1938. - Р. 6-17.Pearse A.G.E., Polak GM. Bifunctional reagents as vapour - and liquid - phase fixatives for immunohistochemistry // Histochem. J. - 1975. - № 7. - Р. 176-186.Pearse A.G.E., Polak GM. Bifunctional reagents as vapour - and liquid - phase fixatives for immunohistochemistry // Histochem. J. - 1975. - № 7. - Р. 176-186.Rachman J., Barrow B.A., Levy J.C. and Turner R.C. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon- like peptide-1 (GLP-1) in subjects with NIDDM // Diabetologia. - 1997. - № 40. - Р. 205-211.Rachman J., Barrow B.A., Levy J.C. and Turner R.C. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon- like peptide-1 (GLP-1) in subjects with NIDDM // Diabetologia. - 1997. - № 40. - Р. 205-211.Nauck M., Frid A., Hermansen K., Shah N.S., Tankova T., Mitha I.H., Zdravkovic M., Düring M., Matthews D.R.. Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study // Diabetes Care. - 2009. - № 32. - Р. 84-90.Nauck M., Frid A., Hermansen K., Shah N.S., Tankova T., Mitha I.H., Zdravkovic M., Düring M., Matthews D.R.. Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study // Diabetes Care. - 2009. - № 32. - Р. 84-90.Knudsen LB., Nielsen PF., Huusfeldt PO., Johansen NL., Madsen K, Freddy Z. Pedersen, Henning Thøgersen, Michael Wilken, and Henrik Agersø. Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration // J. Med. Chem. - 2000. - № 43. - Р. 1664-1669.Knudsen LB., Nielsen PF., Huusfeldt PO., Johansen NL., Madsen K, Freddy Z. Pedersen, Henning Thøgersen, Michael Wilken, and Henrik Agersø. Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration // J. Med. Chem. - 2000. - № 43. - Р. 1664-1669.Marre M., Shaw J., Brändle M., Bebakar W.M.W., Kamaruddin N.A., Strand J., Zdravkovic M., Le Thi T.D., Colagiuri S. Liraglutide, a oncedaily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) // Diabetic Medicine. - 2009. - № 26. - Р. 268-278.Marre M., Shaw J., Brändle M., Bebakar W.M.W., Kamaruddin N.A., Strand J., Zdravkovic M., Le Thi T.D., Colagiuri S. Liraglutide, a oncedaily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) // Diabetic Medicine. - 2009. - № 26. - Р. 268-278.Garber A., Henry R., Ratner R., Garcia-Hernandez P.A., Rodriguez-Pattzi H., Olvera-Alvarez I., Hale P.M., Zdravkovic M., Bode B., for the LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double- blind, parallel-treatment trial // Lancet. - 2009. - № 373. - Р. 481.Garber A., Henry R., Ratner R., Garcia-Hernandez P.A., Rodriguez-Pattzi H., Olvera-Alvarez I., Hale P.M., Zdravkovic M., Bode B., for the LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double- blind, parallel-treatment trial // Lancet. - 2009. - № 373. - Р. 481.Russell-Jones D., Vaag A., Schmitz O., Sethi B.K., Lalic N., et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial // Diabetologia. - 52. - Р. 2046-2055.Russell-Jones D., Vaag A., Schmitz O., Sethi B.K., Lalic N., et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial // Diabetologia. - 52. - Р. 2046-2055.Zinman B., Gerich J., Buse J.B., Lewin A., Schwartz S., Raskin P., Hale P.M., Zdravkovic M., Blonde L., and the LEAD-4 Study Investigators // Diabetes Care. - 2009. - № 32. - Р. 1224-1230.Zinman B., Gerich J., Buse J.B., Lewin A., Schwartz S., Raskin P., Hale P.M., Zdravkovic M., Blonde L., and the LEAD-4 Study Investigators // Diabetes Care. - 2009. - № 32. - Р. 1224-1230.Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study // Lancet. - 2002. - № 359. - Р. 824-830.Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study // Lancet. - 2002. - № 359. - Р. 824-830.Gutzwiller J.-P., Tschopp S., Bock A., Zehnder C.E., Huber A.R., Kreyenbuehl M., Gutmann H., Drewe J., Henzen C., Goeke B., Beglinger C. Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men // J. Clin. Endocrinol. Metab. - 2004. - № 89. - Р. 3055-3061.Gutzwiller J.-P., Tschopp S., Bock A., Zehnder C.E., Huber A.R., Kreyenbuehl M., Gutmann H., Drewe J., Henzen C., Goeke B., Beglinger C. Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men // J. Clin. Endocrinol. Metab. - 2004. - № 89. - Р. 3055-3061.Sokos G.G., Nikolaidis L.A., Mankad S., Elahi D., Shannon R.P. Glucagon- Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients With Chronic Heart Failure // J. Cardiac. Failure. - 2006. - № 12. - Р. 694-699.Sokos G.G., Nikolaidis L.A., Mankad S., Elahi D., Shannon R.P. Glucagon- Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients With Chronic Heart Failure // J. Cardiac. Failure. - 2006. - № 12. - Р. 694-699.Nyström T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahrén B., Sjöholm Å. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease // Am. J. Phisiol. Endocrinol Metab. - 2004. - № 287. - Р. E1209-1215.Nyström T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahrén B., Sjöholm Å. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease // Am. J. Phisiol. Endocrinol Metab. - 2004. - № 287. - Р. E1209-1215.Jendle J., Nauck M. A., Matthews D. R., Frid A., Hermansen K., Düring M., Zdravkovic M., Strauss B. J. and Garber A. J., on behalf of the LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue // Diabetes Obes. Metab. - 2009. - № 11. - Р. 1163-1172.Jendle J., Nauck M. A., Matthews D. R., Frid A., Hermansen K., Düring M., Zdravkovic M., Strauss B. J. and Garber A. J., on behalf of the LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue // Diabetes Obes. Metab. - 2009. - № 11. - Р. 1163-1172.Plutzky L. et al. // Eur Heart J. - 2009. - № 30(Suppl.1). - Р. 917.Plutzky L. et al. // Eur Heart J. - 2009. - № 30(Suppl.1). - Р. 917.Plutzky J., Poulter N.R., Falahati A., Toft A.D., Davidson M.H. Abstract 818: Plasminogen Activator Inhibitor-1 is Reduced by the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide When Used in the Treatment of Type 2 Diabetes // Circulation. - 2009. - № 120. - Р. S397.Plutzky J., Poulter N.R., Falahati A., Toft A.D., Davidson M.H. Abstract 818: Plasminogen Activator Inhibitor-1 is Reduced by the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide When Used in the Treatment of Type 2 Diabetes // Circulation. - 2009. - № 120. - Р. S397.

The authors declare that there are no conflicts of interest present.